Myriad Asks Fed. Circ. To Block Ambry Cancer Test In IP Row
Myriad Genetics Inc. on Friday asked the Federal Circuit to revive its bid for an injunction on Ambry Genetics Corp.'s cancer-testing products, arguing the lower court judge incorrectly held that Myriad's...To view the full article, register now.
Already a subscriber? Click here to view full article